Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Sartore Bianchi, Andrea ^a   Ardini, Elena ^a,b   Bosotti, Roberta ^a,b   Amatu, Alessio ^a,b   Valtorta, Emanuele ^a   Somaschini, Alessio ^a   Raddrizzani, Laura ^a,b   Palmeri, Laura ^a   Banfi, Patrizia ^a   Bonazzina, Erica ^a   Misale, Sandra ^c,e   Marrapese, Giovanna ^a   Leone, Antonella ^b   Alzani, Rachele ^b   Luo, David ^f   Hornby, Zachary ^f   Lim, Jonathan ^f   Veronese, Silvio ^h   Vanzulli, Angelo ^h   Bardelli, Alberto ^c,d   Martignoni, Marcella ^g   Davite, Cristina ^g   Galvani, Arturo ^b   Isacchi, Antonella ^b   Siena, Salvatore ^a   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f Ignyta   (United States)

^g Department of Oncology   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENTRECTINIB; LAMIN A; LAMIN C; NEUROTROPHIC TYROSINE KINASE RECEPTOR 1; PROTEIN TYROSINE KINASE A; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; LMNA PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TFG PROTEIN, HUMAN;

AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RESISTANCE; CASE REPORT; DRUG EFFICACY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; METASTATIC COLORECTAL CANCER; ONCOGENE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LAMIN TYPE A; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA;

EID: 84954071006     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv306     Document Type: Article

References (12)

1. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
2. Ardini E, Bosotti R, Borgia AL, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8(8):1495-1507.
3. Bosotti R, Veronese S, Somaschini A, et al. Identification of a TPM3TRKA rearrangement in human colon carcinoma, and development of a methodology to identify patients for treatment with TRK inhibitors. Presented at the 2013 Annual Meeting of the Associazione Italiana Oncologia Medica (AIOM), October 2013; Milan, Italy.
4. Ardini E, Menichincheri M, Banfi P, et al. The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models. Presented at AACR Annual Meeting, April 6-10 2013; Washington, DC.
5. Ardini E, Menichincheri M, Banfi P, et al. In vitro and in vivo activity of NMSE628 against ALK mutations resitant to Xalkori. Presented at the AACR-NCIEORTC International Conference: Molecular Targets and Cancer Therapeutics, November 12-16, 2011; San Francisco, CA, USA (Abstract #A232).
6. Siena S, Drillon A, Ou S-H, et al. Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. European Journal of Cancer Volume 50, Supplement 3, September 2015.
7. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319(6056):743-748.
8. Lopez-Mejia IC, Vautrot V, De Toledo M, et al. A conserved splicing mechanism of the LMNA gene controls premature aging. Hum Mol Genet. 2011;20(23):4540-4555.
9. Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
10. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479-1484.
11. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469-1472.
12. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772-787.